Literature DB >> 11782257

The rhesus model of Lyme neuroborreliosis.

A R Pachner1, H Gelderblom, D Cadavid.   

Abstract

Similarity of pathology and disease progression make the non-human primate (NHP) model of Lyme neuroborreliosis appropriate and valuable. In the NHP model of Lyme neuroborreliosis, spirochetal density in the nervous system and other tissues has been measured by polymerase chain reaction and correlated to anti-Borrelia burgdorferi antibody in the serum and cerebrospinal fluid and to inflammation in tissues. Despite the demonstrable presence of Borrelia burgdorferi, the causative agent of Lyme borreliosis, only minor inflammation of the central nervous system occurs, though inflammation can be demonstrated in other tissues. Infected animals also develop anti-Borrelia burgdorferi antibody in the serum, although increased amplitude of antibody is not predictive of higher levels of infection. The NHP model continues to provide important insight into the disease process in humans.

Entities:  

Mesh:

Year:  2001        PMID: 11782257     DOI: 10.1034/j.1600-065x.2001.1830115.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  20 in total

1.  Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi.

Authors:  Vinita S Chauhan; David G Sterka; David L Gray; Kenneth L Bost; Ian Marriott
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

2.  OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human lyme disease patients.

Authors:  P Scott Hefty; Chad S Brooks; Amy M Jett; Gary L White; Stephen K Wikel; Ronald C Kennedy; Darrin R Akins
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Humoral immune response associated with lyme borreliosis in nonhuman primates: analysis by immunoblotting and enzyme-linked immunosorbent assay with sonicates or recombinant proteins.

Authors:  A R Pachner; D Dail; L Li; L Gurey; S Feng; E Hodzic; S Barthold
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

4.  Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis.

Authors:  Jan D Lünemann; Harald Gelderblom; Mireia Sospedra; Jacqueline A Quandt; Clemencia Pinilla; Adriana Marques; Roland Martin
Journal:  Infect Immun       Date:  2006-10-23       Impact factor: 3.441

5.  Targeting CXCL13 During Neuroinflammation.

Authors:  Amanda K Huber; David N Irani
Journal:  Adv Neuroimmune Biol       Date:  2015-11-13

Review 6.  A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease.

Authors:  Gary P Wormser; Franc Strle; Eugene D Shapiro; Raymond J Dattwyler; Paul G Auwaerter
Journal:  Diagn Microbiol Infect Dis       Date:  2016-11-12       Impact factor: 2.803

7.  Borrelia burgdorferi transcriptome in the central nervous system of non-human primates.

Authors:  Sukanya Narasimhan; Melissa J Caimano; Fang Ting Liang; Felix Santiago; Michelle Laskowski; Mario T Philipp; Andrew R Pachner; Justin D Radolf; Erol Fikrig; Melissa J Camaino
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

Review 8.  The pathogenesis of lyme neuroborreliosis: from infection to inflammation.

Authors:  Tobias A Rupprecht; Uwe Koedel; Volker Fingerle; Hans-Walter Pfister
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

Review 9.  Lyme disease.

Authors:  Patricia K Coyle
Journal:  Curr Neurol Neurosci Rep       Date:  2002-11       Impact factor: 5.081

10.  Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis.

Authors:  Geeta Ramesh; Juan T Borda; Jason Dufour; Deepak Kaushal; Ramesh Ramamoorthy; Andrew A Lackner; Mario T Philipp
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.